Articles tagged "Kidney transplantation"

2018 American Transplant Congress
T Cell Exhaustion in Kidney Transplant Patients
M. Fribourg,¹ C. Fischman,² L. Anderson,² B. Burrell,³ P. Heeger,² P. Cravedi.²
¹Department of Neurology, Icahn School of Medicine, New York; ²Department of Medicine, Icahn School of Medicine, New York; ³Immune Tolerance Network, Bethesda.
Background: T cell exhaustion is a dysfunctional state that arises during chronic infection and cancer in response to persistence of high antigenic load. Whether chronic…
2018 American Transplant Congress
Natural History and Determinants of Infectious Complications after Kidney Transplantation: A Nationwide Prospective Population Based Cohort
A. Scelma, M. Perrier, O. Lortholary, S. Girerd, C. Kerleau, V. Garrigues, F. Buron, N. Kamar, C. Legendre, Y. Bouatou, C. Lefaucheur, M. Giral, A. Loupy.
Paris Transplant Group, Paris, France.
Background: Although Infectious complications are a major cause of morbidity and mortality in KTR, little is known about their natural history and determinants at a…
2018 American Transplant Congress
The Risk Factors of Acute Rejection in Patients with BK Nephropathy after the Reduction of Immunosuppression
C. Baek,¹ H. Kim,¹ W. Yang,¹ D. Han,² S-.K. Park.¹
¹Department of Internal Medicine, Division of Nephrology, Asan Medical Center, Seoul, Republic of Korea; ²Department of Surgery, Asan Medical Center, Seoul, Republic of Korea.
Background: BK nephropathy (BKN) affects graft function and increases the risk of graft failure. The reduction of immunosuppression is the main treatment for BKN. However,…
2018 American Transplant Congress
Not All HLA Mismatches Are Equal: Determining the Relative De Novo DSA Induction Capacity of HLA Mismatches
V. Jucaud,¹ L. Rebellato,² K. Briley,² A. Maldonado,³ C. Haisch,² P. Bolin,² S. Kendrick,⁴ H. Jones,⁴ K. McLawhorn,⁴ D. Leeser,² M. Everly.¹
¹Terasaki Research Institute, Los Angeles, CA; ²East Carolina University, Greenville, NC; ³Vidant Medical Center, Greenville, NC; ⁴Eastern Nephrology Associates, Greenville, NC.
We studied the immunogenicity, defined as the development of de novo DSA (dnDSA), of HLA-A, -B, -DR and -DQ MM (serological) in a cohort of…
2018 American Transplant Congress
Reducing No-Show Rate and Filling Cancelled Appointments: Multi-Faceted Interventions Markedly Reduced Time to Kidney Transplant Evaluation
E. Gibney, K. Payne, C. Fowler.
Piedmont Transplant Institute, Piedmont Atlanta Hospital, Atlanta, GA.
Introduction: Time from referral to appointment for kidney transplant evaluation is an important metric. Demands of dialysis schedules and transportation logistics typically lead to high…
2018 American Transplant Congress
Non-Invasive Proteomics to Detect Biomarkers for Kidney Allograft Dysfunction
M. Watson,¹ M. Srivastava,³ D. Little,¹ O. Eidelman,³ R. Nee,¹ A. Bera,³ J. Karaian,³ D. Oliver,¹ H. Pollard,³ R. Jindal.²
¹Nephrology, USU-Walter Reed, Bethesda, MD; ²Surgery, USU-Walter Reed, Bethesda, MD; ³Anamtomy, Physiology and Genetics, USU-School of Medicine, Bethesda, MD.
Background: Non-invasive biomarkers are needed for monitoring patients to predict early acute rejection (AR). We hypothesized that protein biomarkers released from rejecting allograft tissues can…
2018 American Transplant Congress
Urinary TIMP-2 Predicts the Presence and Duration of Delayed Graft Function in DCD Kidney Transplant Recipients
J. Bank,¹ R. Ruhaak,² D. Soonawala,¹ F. Romijn,² C. van Kooten,¹ C. Cobbaert,² H. de Fijter.¹
¹Nephrology, Leiden University Medical Center, Leiden, Netherlands; ²Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, Netherlands.
Introduction: Tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) are promising biomarkers in acute kidney injury. Here, we investigated the performance…
2018 American Transplant Congress
C1q-Binding Donor-Specific Anti-HLA Antibodies for Clinical Decision Making in Kidney Recipients with Antibody-Mediated Rejection Receiving Standard of Care Treatment
C. Lefaucheur,¹ D. Viglietti,¹ Y. Bouatou,¹ O. Aubert,¹ A. Zeevi,² A. Loupy.¹
¹Paris Translational Research Center for Organ Transplantation, Paris, France; ²University of Pittsburgh Medical Center, Pittsburgh.
One of the major issues in the clinical management of kidney recipients with ABMR is the lack of early and reliable markers that surrogate long-term…
2018 American Transplant Congress
Antibody Mediated Kidney Transplant Rejection Treated with Bortezomib – Case Series from a Single Center
G. Piecha,¹ R. Król,² H. Karkoszka,¹ A. Wiecek.¹
¹Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland; ²Department of General, Vascular and Transplantation Surgery, Medical University of Silesia, Katowice, Poland.
Acute antibody mediated kidney transplant rejection (ABMR) is not a frequent complication but may have a catastrophic consequences for graft survival. Between January 2015 and…
2018 American Transplant Congress
Immuoadsorption-Based Desensitization in Highly Sensitized Patients Awaiting Deceased Donor Kidney Transplantation.
C. Bureau, P. Galichon, Y. Luque, N. Ouali, E. Rondeau, C. Rafat.
Urgences Néphrologiques et Transplantation Rénale, Tenon Hospital, APHP, Paris, France.
An estimated 30% of patients on the waiting list are deemed highly sensitized due to preexisting anti-HLA antibodies often irrevocably precluding kidney transplantation (KT). Immunoadsorption…